Nature Communications (Feb 2021)
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
- Hayato Mizuta,
- Koutaroh Okada,
- Mitsugu Araki,
- Jun Adachi,
- Ai Takemoto,
- Justyna Kutkowska,
- Kohei Maruyama,
- Noriko Yanagitani,
- Tomoko Oh-hara,
- Kana Watanabe,
- Keiichi Tamai,
- Luc Friboulet,
- Kazuhiro Katayama,
- Biao Ma,
- Yoko Sasakura,
- Yukari Sagae,
- Mutsuko Kukimoto-Niino,
- Mikako Shirouzu,
- Satoshi Takagi,
- Siro Simizu,
- Makoto Nishio,
- Yasushi Okuno,
- Naoya Fujita,
- Ryohei Katayama
Affiliations
- Hayato Mizuta
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
- Koutaroh Okada
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
- Mitsugu Araki
- Graduate School of Medicine, Kyoto University
- Jun Adachi
- Laboratory of Proteomics for Drug Discovery, Laboratory of Clinical and Analytical Chemistry, Center for Drug Design Research, National Institutes of Biomedical Innovation, Health and Nutrition
- Ai Takemoto
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
- Justyna Kutkowska
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
- Kohei Maruyama
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
- Noriko Yanagitani
- Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research
- Tomoko Oh-hara
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
- Kana Watanabe
- Department of Respiratory Medicine, Miyagi Cancer Center
- Keiichi Tamai
- Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute
- Luc Friboulet
- INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay
- Kazuhiro Katayama
- Laboratory of Molecular Targeted Therapeutics, School of Pharmacy, Nihon University
- Biao Ma
- Research and Development Group for In Silico Drug Discovery, Center for Cluster Development and Coordination (CCD), Foundation for Biomedical Research and Innovation at Kobe (FBRI)
- Yoko Sasakura
- Research and Development Group for In Silico Drug Discovery, Center for Cluster Development and Coordination (CCD), Foundation for Biomedical Research and Innovation at Kobe (FBRI)
- Yukari Sagae
- Graduate School of Medicine, Kyoto University
- Mutsuko Kukimoto-Niino
- RIKEN Center for Biosystems Dynamics Research
- Mikako Shirouzu
- RIKEN Center for Biosystems Dynamics Research
- Satoshi Takagi
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
- Siro Simizu
- Department of Applied Chemistry, Faculty of Science and Technology, Keio University
- Makoto Nishio
- Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research
- Yasushi Okuno
- Graduate School of Medicine, Kyoto University
- Naoya Fujita
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
- Ryohei Katayama
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
- DOI
- https://doi.org/10.1038/s41467-021-21396-w
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 16
Abstract
Resistance to ALK inhibitors such as lorlatinib often arise due to on-target mutations. Here, the authors show the multi-kinase inhibitor gilteritinib is effective against different mutations that arise during lorlatinib in ALK fusion positive lung cancer to cause resistance.
